Magazine article Clinical Psychiatry News

Rx Mix-Ups Prompt Reminyl Name Change

Magazine article Clinical Psychiatry News

Rx Mix-Ups Prompt Reminyl Name Change

Article excerpt

Janssen Pharmaceutica has agreed to change the name of its Alzheimer's drug Reminyl in response to inadvertent dispensing of the oral blood glucose-lowering drug Amaryl in its place. The mix-ups have resulted in cases of severe hypoglycemia and other serious adverse events, including one fatality.

In a Dec. 22, 2004, letter, the Food and Drug Administration acknowledged Janssen's intention to change the name of all Reminyl products.

At press time, the new name had not been announced.

Amaryl is the trade name for glimepiride, which is approved for treating type 2 diabetes and is marketed by Aventis. Reminyl has been the trade name for galantamine, which is approved for mild to moderate dementia of the Alzheimer's type and is marketed by Janssen Pharmaceutica.

Spontaneous reports submitted to the FDA and to the U.S. Pharmacopeia have described prescriptions that have been "incorrectly written, interpreted, labeled, and/or filled due to the similarity" between the two trade names, according to a "Dear Health Care Provider" letter issued by Janssen. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.